Effectiveness of a Physical Activity and Diet Program in Patients With Psychotic Disorder (CapiCor) (CapiCor)

August 31, 2016 updated by: Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina

Effectiveness of a Physical Activity and Diet Program, Coordinated Between Primary Care and Mental Health, to Modify Cardiovascular Risk Factors in Patients With Schizophrenia or Bipolar Disorder (CapiCor)

The aim is to evaluate the effectiveness of an intervention based on a program of physical activity and diet coordinated between primary care teams (PCT) and Mental Health Centres (MHC) to modify the weekly physical activity (PA) amount, body mass index (BMI) and waist circumference in patients with severe mental disorder diagnoses. To assess changes in cardiovascular risk, quality of life and lifestyles, secondarily. Methods: A randomized clinical trial with a control group, of one year of follow-up, carried out in four MHC Barcelona and Santa Coloma, and PCT of reference. The investigators studied patients aged 18 - 65 years old, diagnosed with schizophrenia, schizoaffective or bipolar disorder, with antipsychotic medication and a low level of PA. 240 patients will be selected in each group (difference to be detected in the BMI:> 1.89 kg/m2; common SD: 6.2, 30% loss). Intervention: group educational PA program (basically walking) of 24 sessions over 12 weeks, and diet (8 sessions in the first 8 weeks) by nurses and specialists in PA. Key measurements: level of PA (IPAQ questionnaire), physical examinations: BMI, waist circumference, blood pressure, cardiovascular risk, quality of life (SF-36), smoking habits, dietary habits (PREDIMED questionnaire), analytical parameters: cholesterol , triglycerides, blood glucose. Evaluations will be masked and conducted at 0, 3, 6 and 12 months. Analysis of variance for repeated measures to adjust for differences attributable to the effect of the intervention for potential confounders: pharmacological treatment, care level of intervention and mental state.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

332

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
      • Barcelona, Spain, 08007
        • Jordi Gol i Gurina Foundation

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • age between 18 and 65 years old,
  • understand Catalan or Spanish
  • will be located for at least twelve months.
  • Psychiatric disorders with ICD-10 diagnosis codes: F20*, F31* and F25*.
  • Taking an antipsychotic drug at, a least, three months
  • Low physical activity level

Exclusion Criteria:

  • Active addiction to psychoactive drugs, except tobacco.
  • Pregnancy
  • Diseases that doesn't allow physical activity
  • Psychotic acute exacerbation in the last month

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Physical and diet educational group
group educational PA program (basically walking) of 24 sessions over 12 weeks, and diet (16 sessions in the first 8 weeks), carried out by mental health nurses.
Behavioral: Physical and diet educational group
educational group of: physical activity program (basically walking) of 24 sessions over 12 weeks, and diet (16 sessions in the first 8 weeks, carried out by mental health nurses.
No Intervention: Usual clinical care

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Change in weekly level of physical activity (IPAQ questionnaire),
Time Frame: : the outcome measure is studied at 3, 6 and 12 months
: the outcome measure is studied at 3, 6 and 12 months
Body mass index (kg/m²)
Time Frame: : the outcome measure is studied at 3, 6 and 12 months
: the outcome measure is studied at 3, 6 and 12 months
waist circumference (cm)
Time Frame: : the outcome measure is studied at 3, 6 and 12 months
: the outcome measure is studied at 3, 6 and 12 months

Secondary Outcome Measures

Outcome Measure
Time Frame
blood pressure (mm hg)
Time Frame: the outcome measure is studied at 3, 6 and 12 months
the outcome measure is studied at 3, 6 and 12 months
cardiovascular risk with the Regicor coronary risk to 10 years
Time Frame: the outcome measure is studied at 3, 6 and 12 months
the outcome measure is studied at 3, 6 and 12 months
Quality of life (SF-36 questionnaire)
Time Frame: the outcome measure is studied at 3, 6 and 12 months
the outcome measure is studied at 3, 6 and 12 months
Smoking habits: smoker/ ex-smoker/no-smoker. Number of cigarettes per day.
Time Frame: the outcome measure is studied at 3, 6 and 12 months
the outcome measure is studied at 3, 6 and 12 months
Dietary habits (PREDIMED questionnaire)
Time Frame: the outcome measure is studied at 3, 6 and 12 months
the outcome measure is studied at 3, 6 and 12 months
Analytical parameters: cholesterol , triglycerides, blood glucose mg/100 ml.
Time Frame: the outcome measure is studied at 3, 6 and 12 months
the outcome measure is studied at 3, 6 and 12 months

Other Outcome Measures

Outcome Measure
Time Frame
Clinical Global Impression, CGI
Time Frame: the outcome measure is studied at 3, 6 and 12 months
the outcome measure is studied at 3, 6 and 12 months
BPRS (Brief Psychiatric Rating Scale)
Time Frame: the outcome measure is studied at 3, 6 and 12 months
the outcome measure is studied at 3, 6 and 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina

Collaborators

Carlos III Health Institute

Investigators

  • Principal Investigator: MARIA-ISABEL FERNANDEZ-SAN-MARTIN, PH, Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2012

Primary Completion (Actual)

March 1, 2015

Study Completion (Actual)

December 1, 2015

Study Registration Dates

First Submitted

November 14, 2012

First Submitted That Met QC Criteria

November 19, 2012

First Posted (Estimate)

November 20, 2012

Study Record Updates

Last Update Posted (Estimate)

September 1, 2016

Last Update Submitted That Met QC Criteria

August 31, 2016

Last Verified

August 1, 2016

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PI11/01861

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Schizophrenic Disorders

Clinical Trials on Physical and diet educational group

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe